



A multi-center, randomized, double-blind, active and placebo-controlled study to investigate the efficacy and safety of ligelizumab (QGE031) in the treatment of Chronic Spontaneous Urticaria (CSU) in adolescents and adults inadequately controlled with H1-antihistamines

05/04/2025 01:46:08

Main Information

Primary registry identifying number

LBCTR2019020192

Protocol number

CQGE031C2303

MOH registration number

37979/2018

Study registered at the country of origin

Yes

Study registered at the country of origin: Specify

Type of registration

Retrospective

Type of registration: Justify

LCTR was recently initiated, original file was previously submitted by Paper

Date of registration in national regulatory agency

13/09/2018

Primary sponsor

Novartis Pharma Services Inc.

Primary sponsor: Country of origin

Novartis Pharmaceuticals

Date of registration in primary registry

26/12/2020

Date of registration in national regulatory agency

13/09/2018

Public title

A multi-center, randomized, double-blind, active and placebo-controlled study to investigate the efficacy and safety of ligelizumab (QGE031) in the treatment of Chronic Spontaneous Urticaria (CSU) in adolescents and adults inadequately controlled with H1-antihistamines

Acronym

Pearl 2

Scientific title

A multi-center, randomized, double-blind, active and placebo-controlled study to investigate the efficacy and safety of ligelizumab (QGE031) in the treatment of Chronic Spontaneous Urticaria (CSU) in adolescents and adults inadequately controlled with H1-antihistamines

Acronym

Brief summary of the study: English



The purpose of this study is to establish efficacy and safety of ligelizumab in adolescent and adult subjects with CSU who remain symptomatic despite standard of care treatment by demonstrating better efficacy over omalizumab.

The study population will consist of approximately 1050 male and female subjects aged ≥ 12 years who have been diagnosed with Chronic Spontaneous Urticaria CSU and who remain symptomatic despite the use of H1-antihistamines. Of these, approximately 1000 adults and 50 adolescents are planned for inclusion in the study.

This is a multi-center, randomized, double-blind, active- and placebo-controlled, parallel-group study. There is a screening period of up to 28 days, a 52 week double-blind treatment period, and a 12 week post-treatment follow-up period.

Brief summary of the study: Arabic

دراسة متعددة المراكز وعشوائية التوزيع ومزدوجة التعمية ونشطة قائمة على مقارنة تأثير الدواء بدواء وهمي لدراسة فعالية وسلامة دواء ليجيليزوماب لدى المراهقين والبالغين H1 في علاج الشرى التلقائي المزمن غير المسيطر عليه بشكل كافٍ بمضادات الهستامين (QGE031)

Health conditions/problem studied: Specify

Patients with chronic spontaneous urticaria

Interventions: Specify

IMP: Ligelizumab

Comparators: Omalizumab and Placebo

Key inclusion and exclusion criteria: Inclusion criteria

- Signed informed consent must be obtained prior to participation in the study. The subject's, parent's or legal guardian's signed written informed consent and child's assent, if appropriate, must be obtained before any assessment is performed. Of note, if the subject reaches age of consent (age as per local law) during the study, they will also need to sign the corresponding study Informed Consent Form (ICF) at the next study visit.
- Male and female subjects ≥ 12 years of age at the time of screening.
- CSU diagnosis for ≥ 6 months.
- Diagnosis of CSU refractory to H1-AH at approved doses at the time of randomization, as defined by all of the following:
 - The presence of itch and hives for ≥ 6 consecutive weeks at any time prior to Visit 1 (Day - 28 to Day -14) despite current use of non-sedating H1-antihistamine
 - UAS7 score (range 0-42) ≥ 16 and HSS7 (range 0-21) ≥ 8 during the 7 days prior to randomization (Visit 110, Day 1)
 - Subjects must be on H1-antihistamine at only approved doses for treatment of CSU starting at Visit 1 (Day -28 to Day -14)
 - Willing and able to complete a daily symptom eDiary for the duration of the study and adhere to the study visit schedules

Key inclusion and exclusion criteria: Gender

Both

Key inclusion and exclusion criteria: Specify gender

Key inclusion and exclusion criteria: Age minimum

12

Key inclusion and exclusion criteria: Age maximum

99

Key inclusion and exclusion criteria: Exclusion criteria

- History of hypersensitivity to any of the study drugs or their excipients or to drugs of similar chemical classes (i.e. to murine, chimeric or human antibodies).
- Subjects having a clearly defined cause of their chronic urticaria, other than CSU. This includes, but is not limited to, the following: symptomatic dermatographism (urticaria factitia), cold-, heat-, solar-, pressure-, delayed pressure-, aquagenic-, cholinergic- or contact-urticaria.
- Diseases, other than chronic urticaria, with urticarial or angioedema symptoms such as urticarial vasculitis, erythema multiforme, cutaneous mastocytosis (urticaria pigmentosa) and hereditary or acquired angioedema (eg. due to C1 inhibitor deficiency).
- Subjects with evidence of helminthic parasitic infection as evidenced by stools being positive for a pathogenic organism according to local guidelines. All subjects will be screened at Visit 1. If stool testing is positive for pathogenic organism, the subject will not be randomized and will not be allowed to rescreen.
- Any other skin disease associated with chronic itching that might influence in the investigators opinion the study evaluations and results (e.g. atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus, etc.).
- Prior exposure to ligelizumab or omalizumab.
- Any H2 antihistamine, LTRA (montelukast or zafirlukast) or H1 antihistamines use at greater than approved doses after Visit 1.

Type of study

Interventional

Type of intervention

Pharmaceutical

Type of intervention: Specify type

N/A



Trial scope

Other

Trial scope: Specify scope

Study design: Allocation

Randomized controlled trial

Study design: Masking

Blinded (masking used)

Study design: Control

Active

Study phase

3

Study design: Purpose

Treatment

Study design: Specify purpose

N/A

Study design: Assignment

Parallel

Study design: Specify assignment

N/A

IMP has market authorization

No

IMP has market authorization: Specify

Name of IMP

Ligelizumab

Year of authorization

Month of authorization

Type of IMP

Immunological

Pharmaceutical class

Humanized monoclonal antibody of the subtype IgG1/ (anti-IgE)

Therapeutic indication

Patients with chronic spontaneous urticaria inadequately controlled with H1-antihistamines

Therapeutic benefit

Absolute change from baseline in UAS7 at Week 12

Study model

N/A

Study model: Explain model

N/A

Study model: Specify model

N/A

Time perspective

N/A

Time perspective: Explain time perspective

N/A

Time perspective: Specify perspective

N/A

Target follow-up duration

Target follow-up duration: Unit

Number of groups/cohorts

Biospecimen retention

Biospecimen description



| | |
|---|--|
| Samples without DNA | Central lab name, address and contact details: Q ² Solutions The Alba Campus Rosebank Livingston EH54 7EG United Kingdom |
| Target sample size 22 | Lab tests to be preformed: Hematology, Clinical chemistry , Coagulation PK/PD:ligelizumab/total IgE Anti-Drug(ligelizumab) antibodies (ADA) Chronic urticaria (CU) index panel (CU index, thyroid peroxidase IgG,thyroglobulin IgG) IgE- autoantibodies,Total tryptase Urine dipstick, Urine Pregnancy Test . Actual enrollment target size 23 |
| Date of first enrollment: Type Actual | Date of first enrollment: Date 19/02/2019 |
| Date of study closure: Type Actual | Date of study closure: Date 30/07/2021 |
| Recruitment status Recruiting | Recruitment status: Specify |
| Date of completion 28/02/2020 | |
| IPD sharing statement plan No | IPD sharing statement description Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com |
| Additional data URL https://clinicaltrials.gov/ct2/show/record/NCT03580356?term=CQGE031C2303&rank=1 | |
| Admin comments | |
| Trial status Approved | |

Secondary Identifying Numbers

| Full name of issuing authority | Secondary identifying number |
|---|------------------------------|
| National Institute of Health (clinicaltrials.gov) | NCT03580369 |

Sources of Monetary or Material Support

| Name |
|-------------------------------|
| Novartis Pharma Services Inc. |



Secondary Sponsors

| Name |
|------|
| NA |

Contact for Public/Scientific Queries

| Contact type | Contact full name | Address | Country | Telephone | Email | Affiliation |
|--------------|-------------------|------------|---------|------------------------|-------------------------------|---|
| Public | Hadi Hamam | Saida | Lebanon | 961 3 795 246 | hadiamam@hotmail.com | Hammoud Hospital |
| Scientific | Hind Khairallah | Sin El Fil | Lebanon | +961 1 512002 Ext. 271 | Hind.Khairallah@fattal.com.lb | Khalil Fattal et Fils s.a.l. |
| Public | Carla Irani | Beirut | Lebanon | 961 3 495 496 | iranica@yahoo.com | Hotel Dieu De France |
| Public | Alfred Ammouy | Beirut | Lebanon | 961 78 820 821 | docalf@yahoo.com | Saint George Hospital University Medical Center |

Centers/Hospitals Involved in the Study

| Center/Hospital name | Name of principles investigator | Principles investigator speciality | Ethical approval |
|--|---------------------------------|------------------------------------|------------------|
| Hammoud Hospital University Medical Center | Dr Hadi Hamam | Dermatology | Approved |
| Hotel Dieu De France | Dr Carla Irani | Immunologist and Allergist | Approved |
| Saint Georges Hospital UMC | Dr Alfred Ammouy | Dermatology | Approved |

Ethics Review

| Ethics approval obtained | Approval date | Contact name | Contact email | Contact phone |
|---|---------------|---------------|------------------------------|---------------------------|
| Hotel Dieu de France | 31/07/2018 | Sami Richa | cue@usj.edu.lb | 961421229 |
| Saint George Hospital University Medical Center | 23/10/2018 | Michel Daher | mndaher@stgeorgehospital.org | 01/441733 |
| Hammoud Hospital University Medical Center | 16/07/2018 | Ahmad Zaatari | zaatari@hammoudhospital.com | 961 (0) 7 723111 ext 1160 |



Countries of Recruitment

| Name |
|--------------------------|
| Australia |
| Belgium |
| Japan |
| Germany |
| Norway |
| Russian Federation |
| Spain |
| United States of America |
| Italy |
| France |
| Tunisia |
| Lebanon |

Health Conditions or Problems Studied

| Condition | Code | Keyword |
|-------------------------------|--------------------------------|-------------------------------|
| chronic spontaneous urticaria | Urticaria, unspecified (L50.9) | chronic spontaneous urticaria |

Interventions

| Intervention | Description | Keyword |
|--|--|--------------------|
| Informed consent, questionnaires, Lab tests, drug administration | Informed consent, questionnaires, Lab tests, drug administration | ICF, Lab, ECG, IMP |

Primary Outcomes

| Name | Time Points | Measure |
|--|-----------------------------------|-----------------------------------|
| Absolute change from baseline in UAS7 | Week 12 | Week 12 |
| Complete itch response is defined as ISS7 :average daily ISS | ISS over the preceding 7 days = 0 | ISS over the preceding 7 days = 0 |



Key Secondary Outcomes

| Name | Time Points | Measure |
|---------------------------------------|-------------|---------|
| Complete absence of hives and itch | week 12 | Week 12 |
| Improvement of severity of itch | week 12 | week12 |
| No impact on subjects quality of life | week 12 | week 12 |

Trial Results

Summary results

Study results globally

Date of posting of results summaries

Date of first journal publication of results

Results URL link

Baseline characteristics

Participant flow

Adverse events

Outcome measures

URL to protocol files